Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.5 USD | +13.64% | -6.25% | +31.58% |
05-30 | NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 | CI |
05-02 | NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.58% | 41.96M | |
+15.85% | 122B | |
+18.91% | 113B | |
+4.43% | 22.84B | |
-18.63% | 20.72B | |
-13.76% | 16.39B | |
-16.61% | 16.51B | |
-43.53% | 15.83B | |
+1.75% | 13.49B | |
+28.07% | 11.67B |
- Stock Market
- Equities
- NXTC Stock
- News NextCure, Inc.
- NextCure Says Preclinical Data of NC181 for Alzheimer's Disease Shows Amyloid Clearance